Evidence map›Paper›PMID 41926663›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Construction of a MOF-Based Snap-Top Delivery Nanosystem for Powerful Dual-Responsive Synergistic Colitis Treatment.

Xin Li, Miao Xu, Heran Li, Huan Jiang, Xin Wang, Lianjun Ma, Ying-Wei Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xin LiInternational Joint Research Laboratory of Nano-Micro Architecture Chemistry, College of Chemistry, Jilin University, Changchun, China.
Miao XuSchool of Pharmacy, China Medical University, Shenyang, China.
Heran LiSchool of Pharmacy, China Medical University, Shenyang, China.
Huan JiangJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Department of Orthodontics, School and Hospital of Stomatology, Jilin University, Changchun, China.
Xin WangInternational Joint Research Laboratory of Nano-Micro Architecture Chemistry, College of Chemistry, Jilin University, Changchun, China.
Lianjun MaChina-Japan Union Hospital, Jilin University, Changchun, China.
Ying-Wei YangInternational Joint Research Laboratory of Nano-Micro Architecture Chemistry, College of Chemistry, Jilin University, Changchun, China.ORCID https://orcid.org/0000-0001-8839-8161

Funding

Fundamental Research Funds for the Central Universities 2025-JCXK-24Liaoning Provincial Youth Science Foundation 2025-YQ-10National Natural Science Foundation of China 82472136Natural Science Foundation of Jilin Province YDZJ202401254ZYTSScientific Research Innovation Capability Support Project for Young Faculty SRICSPYF-BS2025082
6 · The paper itself

Abstract

Oral treatment of inflammatory bowel disease (IBD) faces significant challenges of poor targeting, low bioavailability, and systemic toxicity, necessitating intelligent stimuli-responsive delivery systems. Here, we design and synthesize a pH/hypoxia dual-responsive pendant azobenzene-functionalized MOF (Azo-MOF). The uniformly distributed azobenzene pendants serve as intrinsic gating sites, forming "snap-top" encapsulation with β-cyclodextrin through host-guest interactions that prevent premature 6-mercaptopurine leakage while enabling rapid stimuli-triggered release, creating a postmodification-free supramolecular gated delivery nanosystem (CAMM). CAMM exhibits hypoxia-triggered burst release and alkaline-sustained release, with <5.0% drug leakage during gastrointestinal transit and >90.0% cumulative release at inflammatory sites. Notably, the Azo-MOF carrier scavenges reactive oxygen species through synergy between its conjugated π-system and metal coordination environment, providing antioxidant protection alongside drug delivery. In dextran sulfate sodium-induced colitis models, CAMM outperformed free drug, achieving near-complete weight recovery, downregulating proinflammatory cytokines, restoring intestinal barrier integrity, and rebalancing gut microbiota by enriching Lactobacillus and Bifidobacterium while suppressing opportunistic pathogens. This study integrates targeted delivery, antioxidant therapy, and microbiota modulation, offering an effective strategy for precision IBD treatment.

Indexed as

Azo CompoundsColitisDrug Delivery SystemsInflammatory Bowel DiseasesMetal-Organic FrameworksAnimalsbeta-CyclodextrinsDextran SulfateDisease Models, AnimalMiceazobenzeneAzo Compoundsbeta-CyclodextrinsDextran SulfateMetal-Organic Frameworksdrug deliverymetal–organic frameworksresponsive materialssupramolecular materialssynergistic therapy

Identifiers

PMID41926663
PMCPMC13317788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.